Mirati Presents Results of Adagrasib (MRTX849) in P-I/II KRYSTAL–1 Study for the Treatment of KRAS G12C-Mutated Colorectal Cancer at ESMO 2021
Shots:
- The P-I/II KRYSTAL–1 study evaluates adagrasib (600mg- bid) as monothx. and in combination with cetuximab in patients with heavily pretreated colorectal cancer harboring a KRASG12C mutation following prior systemic therapy
- The therapy showed the clinical activity and broad disease control. As of May 25 & July 9- 2021- 80% of patients received adagrasib mononthx. & 90% with combination; median follow up of 8.9 & 7mos.; response rate (22% & 43%) including unconfirmed PR (1 & 2); DCR (87% & 100%) respectively- m-DoR (4.2mos.) & m-PFS (5.6mos.) in monothx. therapy
- Additionally- the therapy was well-tolerated with a manageable safety profile- grade 3/4 TRAEs (30% in monothx. & 16% in combination)
| Ref: Mirati | Image: Trading View
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com